Skip to main content

Table 2 TFAP2D immunostaining results and prostate cancer phenotype in all cancers, ERG negative cancers, and ERG positive cancers

From: Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion

 TFAP2D IHC result all cancersTFAP2D IHC result in ERG negative cancersTFAP2D IHC result in ERG positive cancers
n
13545
negative (%)
24.3
positive (%)
75.7
p valuen
4722
negative (%)
33.2
positive (%)
66.8
p valuen
3776
negative (%)
11.3
positive (%)
88.7
p value
Tumor stage
 pT2856926.673.4< 0.0001311435.364.7< 0.0001226811.388.70.8159
 pT3a305421.978.198232.467.699810.889.2
 pT3b-4186617.182.961223.276.849511.988.1
Gleason grade
  ≤ 3 + 3239131.868.2< 0.000186542.757.3< 0.000172514.385.70.0256
 3 + 4724624.775.325303466220310.989.1
 3 + 4 Tert.564822.877.221629.670.411711.188.9
 4 + 3135418.881.251825.374.73748.891.2
 4 + 3 Tert.598815.984.130523.976.12117.692.4
  ≥ 4 + 480918.381.728423.676.414313.386.7
Gleason grade quant
 3 + 4 ≤ 5%183927.872.2< 0.000167337.762.3< 0.000155012.787.30.0636
 3 + 4 6–10%181125.174.966334.565.558210.389.7
 3 + 4 11–20%160923.876.257434.365.74889.490.6
 3 + 4 21–30%82521.678.428829.270.82849.290.8
 3 + 4 31–49%68222.177.925630.969.12091288
 4 + 3 50–60%56419.580.521626.973.11688.391.7
 4 + 3 61–80%49517.682.420623.876.21437.792.3
 4 + 3 > 80%12516845219.280.83312.187.9
Lymph node metastasis
 N0814123.876.2< 0.0001272532.667.4< 0.0001214211.488.60.4192
 N+103215.684.428520.779.324213.286.8
Preop. PSA level (ng/ml)
  < 4162421.678.40.010148730.469.60.201752610.689.40.012
 4–10798824.275.8279733.666.4233210.289.8
 10–20284624.875.2103331.868.266114.185.9
  > 20100827.172.938436.563.523115.284.8
Surgical margin
 negative10,76424.875.20.0045374333.666.40.2278298311.588.50.4099
 positive273222.277.896731.568.577710.489.6